External broker reports(aggregated public sources), Mirae Asset Securities

Mirae Asset Securities

External broker reports(aggregated public sources)

Leading full-service brokerage firm in Vietnam. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Phong Phu Pharmaceutical Jsc / Equity Bottom-Up

<ul><li>Phong Phu Corporation (PPH VN) is a textile producer in Southern Vietnam.</li><li>After undergoing restructuring, PPH currently focuses on two segments: yarn and home textile products.</li><li>PPH has a solid advantage in the fiber segment, thanks to its cooperation with Coats (through Coats Phong Phu Ltd. and PPH is the only Vietnamese company providing sewing thread yarn for Coats globally). </li></ul><div class="content-highlight">Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</div>

Phong Phu Corporation (PPH VN) is a textile producer in Southern Vietnam.After undergoing restructuring, PPH currently focuses on two segments: yarn and home textile products.PPH has a solid advantage in the fiber segment, thanks to its cooperation with Coats (through Coats Phong Phu Ltd. and PPH is the only Vietnamese company providing sewing thread yarn for Coats globally). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Phong Phu Corporation (PPH VN) - Solid Performance in 2024

APAC IPOs & Placements, Aequitas Research

Ethan Aw

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Lotus Pharmaceutical / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/lotus-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:20568:1" rel="noopener">Lotus Pharmaceutical (1795 TT)'s</a> majority shareholder, Alvogen Emerging Markets Holdings (AEMH), aims to raise up to US$247m through an affiliated secondary block offering.</li>
<li>The deal is a small one to digest at only 2.4 days of three month ADV, despite being about 8.7% of current mcap. </li>
<li>In this note, we will talk about the placement and run the deal through our ECM framework.</li>
</ul>



Lotus Pharmaceutical (1795 TT)'s majority shareholder, Alvogen Emerging Markets Holdings (AEMH), aims to raise up to US$247m through an affiliated secondary block offering.
The deal is a small one to digest at only 2.4 days of three month ADV, despite being about 8.7% of current mcap. 
In this note, we will talk about the placement and run the deal through our ECM framework.


Lotus Pharmaceutical Placement - Sound Fundamentals but Doesn’t Seem Well Flagged

Pharmaessentia Corp / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/pharmaessentia-corp" target="_blank" data-smartkarma-citation="entities:16461:1" rel="noopener">Pharmaessentia Corp (6446 TT)</a> aims to raise around US$412m (TWD12.6bn) via a GDS issuance. The issuance will be a large one to digest, representing 17.6 days of three month ADV.</li>
<li>The proceeds will be used to accelerate the commercialization, further global clinical trials of BesREMi and conduct R&amp;D in the US for the expansion of the company's product portfolio. </li>
<li>In this note, we will talk about the deal dynamics and run the deal through our ECM framework.</li>
</ul>



Pharmaessentia Corp (6446 TT) aims to raise around US$412m (TWD12.6bn) via a GDS issuance. The issuance will be a large one to digest, representing 17.6 days of three month ADV.
The proceeds will be used to accelerate the commercialization, further global clinical trials of BesREMi and conduct R&amp;D in the US for the expansion of the company's product portfolio. 
In this note, we will talk about the deal dynamics and run the deal through our ECM framework.


PharmaEssentia GDS Issuance - Strong Revenue Growth and Narrowing Losses

Viet Capital Securities Joint Stock Company

Luan Nguyen

Thematic (Sector/Industry)

Thanks to higher disposable income, higher living standards, aging population and higher awareness in general medical knowledge, more people are willing to buy vitamins and dietary supplements to ameliorate their health and immune system. Besides, higher polluted environment and more stressful lifestyle are factors contributing to the sale growth of the category, with current value growth of 10%, reaching VND9.9 trillion in 2016.

Thanks to higher disposable income, higher living standards, aging population and higher awareness in general medical knowledge, more people are willing to buy vitamins and dietary supplements to ameliorate their health and immune system. Besides, higher polluted environment and more stressful lifestyle are factors contributing to the sale growth of the category, with current value growth of 10%, reaching VND9.9 trillion in 2016.

Huge Need for Vitamins, Dietary Supplements and Digestive Remedies in Vietnam

Frontier and emerging markets (Vietnam)

Dylan Waller

Nomadic Equity

Industry Overview I have previously noted Vietnam's pharmaceutical industry as a strategic means to access the rise of domestic consumption in Vietnam, as the country's healthcare spending significantly lags behind emerging Asia, and the industry is projected to deliver double-digit growth in the next five years.  The industry can be considered to be in an infant stage compared to other emerging markets, and now is an interesting time to buy in purely for the potential for domestic growth…

Industry Overview  I have previously noted Vietnam's pharmaceutical industry as a strategic means to access the rise of domestic consumption in Vietnam, as the country's healthcare spending significantly lags behind emerging Asia, and the industry is projected to deliver double-digit growth in the next five years.  The industry can be considered to be in an infant stage compared to other emerging markets, and now is an interesting time to buy in purely for the potential for domestic growth…

Vietnam's Pharmaceutical Industry: Increased Foreign Room and the Rise of Domestic Production

Vietnam

Phong Phu Pharmaceutical JSC is a pharmaceutical company. The Company manufactures medical drugs, tea products, dairy products and trades cosmetics and provides healthcare services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Phong Phu Pharmaceutical Jsc (PPP VN)

Phong Phu Corporation (PPH VN) - Solid Performance in 2024

Phong Phu Corporation (PPH VN) is a textile producer in Southern Vietnam. After undergoing restructuring, PPH currently focuses on two segments:...

Mirae Asset Securities

Lotus Pharmaceutical Placement - Sound Fundamentals but Doesn’t Seem Well Flagged

Lotus Pharmaceutical (1795 TT)'s majority shareholder, Alvogen Emerging Markets Holdings (AEMH), aims to raise up to US$247m through an affiliated...

Ethan Aw

PharmaEssentia GDS Issuance - Strong Revenue Growth and Narrowing Losses

Pharmaessentia Corp (6446 TT) aims to raise around US$412m (TWD12.6bn) via a GDS issuance. In this note, we will talk about the deal dynamics and...

Ethan Aw

Huge Need for Vitamins, Dietary Supplements and Digestive Remedies in Vietnam

Thanks to higher disposable income, higher living standards, aging population and higher awareness in general medical knowledge, more people are...

Luan Nguyen

Vietnam's Pharmaceutical Industry: Increased Foreign Room and the Rise of Domestic Production

Industry OverviewI have previously noted Vietnam's pharmaceutical industry as a strategic means to access the rise of domestic consumption in...

Nomadic Equity

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)